Blackburn David F, Yao Shenzhen, Taylor Jeff G, Alefan Qais, Lix Lisa M, Eurich Dean T, Choudhry Niteesh K
College of Pharmacy and Nutrition, University of Saskatchewan, Saskatoon, Saskatchewan, Canada.
Public Health Surveillance Unit, Vancouver Coastal Health Authority, Vancouver Coastal Health, Vancouver, British Columbia, Canada.
Patient Prefer Adherence. 2024 May 17;18:979-989. doi: 10.2147/PPA.S451012. eCollection 2024.
To measure the impact of beliefs, expectations, side effects, and their combined effects on the risk for medication nonpersistence.
Using a cross-sectional design, individuals from Saskatchewan, Canada who started a new antihypertensive, cholesterol-lowering, or antihyperglycemic medication were surveyed about risk factors for nonpersistence including: (a) beliefs measured by a composite score of three questions asking about the threat of the condition, importance of the drug, and harm of the drug; (b) incident side effects attributed to treatment; and (c) expectations for side effects before starting treatment. Descriptive statistics and logistic regression models were used to quantify the influence of these risk factors on the outcome of nonpersistence. Odds ratios (ORs) and 95% confidence intervals (CIs) were estimated.
Among 3,029 respondents, 5.8% (n=177) reported nonpersistence within four months after starting the new drug. After adjustment for numerous covariates representing sociodemographics, health-care providers, medication experiences and beliefs, both negative beliefs (OR: 7.26, 95%CI: 4.98-10.59) and incident side effects (OR: 8.00, 95%CI: 5.49-11.68) were associated with the highest odds of nonpersistence with no evidence of interaction. In contrast, expectations for side effects before starting treatment exhibited an important interaction with incident side effects following treatment initiation. Among respondents with incident side effects (n=741, 24.5%), the risk for early nonpersistence was 11.5% if they indicated an expectation for side effects before starting the medication compared to 23.6% if they did not (adjusted OR: 0.38, 95%CI: 0.25-0.60).
Expectations for side effects may be a previously unrecognized but important marker of the probability to persist with treatment. A high percentage of new medication users appeared unprepared for the possibility of side effects from their new medication making them less resilient if side effects occur.
评估信念、期望、副作用及其综合影响对药物治疗依从性风险的作用。
采用横断面设计,对加拿大萨斯喀彻温省开始服用新的抗高血压药、降胆固醇药或抗高血糖药的个体进行调查,了解其治疗依从性的风险因素,包括:(a)通过三个问题的综合评分来衡量的信念,这三个问题分别询问病情的威胁、药物的重要性以及药物的危害;(b)归因于治疗的新发副作用;(c)开始治疗前对副作用的期望。采用描述性统计和逻辑回归模型来量化这些风险因素对治疗依从性结果的影响。估计比值比(OR)和95%置信区间(CI)。
在3029名受访者中,5.8%(n = 177)报告在开始新药治疗后的四个月内出现治疗不依从。在对代表社会人口统计学、医疗保健提供者、用药经历和信念的众多协变量进行调整后,负面信念(OR:7.26,95%CI:4.98 - 10.59)和新发副作用(OR:8.00,95%CI:5.49 - 11.68)与治疗不依从的最高几率相关,且无相互作用的证据。相比之下,开始治疗前对副作用的期望与治疗开始后新发副作用存在重要的相互作用。在出现新发副作用的受访者中(n = 741,24.5%),如果他们在开始用药前表示对副作用有预期,早期治疗不依从的风险为11.5%,而如果没有预期则为23.6%(调整后的OR:0.38,95%CI:0.25 - 0.60)。
对副作用的期望可能是一个此前未被认识但对治疗依从性概率很重要的指标。很大比例的新药使用者似乎对新药可能产生的副作用没有做好准备,这使得他们在出现副作用时恢复力较差。